Trial Outcomes & Findings for BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal (NCT NCT03367247)

NCT ID: NCT03367247

Last Updated: 2026-03-10

Results Overview

≥50% consent-to-approach ratio

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

121 participants

Primary outcome timeframe

1 month

Results posted on

2026-03-10

Participant Flow

Participant milestones

Participant milestones
Measure
Phase Ia: 10-week Pre-pilot Patients
In this single arm pre-pilot, patients and caregiver dyads were offered a total of 12 contacts with a BOLSTER study nurse over 10 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase Ia: 10-week Pre-pilot Caregivers
In this single arm pre-pilot, patients and caregiver dyads were offered a total of 12 contacts with a BOLSTER study nurse over 10 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase Ib: 4-week Pre-pilot Patients
The second, abbreviated iteration of the intervention consisted of a single arm pre-pilot, in which patient and caregiver dyads were offered a total of 6 contacts with a BOLSTER study nurse over 4 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase Ib: 4-week Pre-pilot Caregivers
The second, abbreviated iteration of the intervention consisted of a single arm pre-pilot, in which patient and caregiver dyads were offered a total of 6 contacts with a BOLSTER study nurse over 4 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase II (RCT): BOLSTER Arm Patients
BOLSTER provides participants with longitudinal nursing support across care settings, a smartphone-based symptom management app, a print and web-based symptom management toolkit, and advance care planning to ensure that the patient receives care that is congruent with her informed preferences. BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks. Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice.
Phase II (RCT): BOLSTER Arm Caregivers
BOLSTER provides participants with longitudinal nursing support across care settings, a smartphone-based symptom management app, a print and web-based symptom management toolkit, and advance care planning to ensure that the patient receives care that is congruent with her informed preferences. BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks. Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice.
Phase II (RCT): EDP Arm Patients
Enhanced Discharge Planning (EDP): EDP provides patients and caregivers a single session of education and skills training, symptom management, and support. The EDP participants received medication education, self-management strategies for symptoms, skills training, and a list of red flag symptoms and numbers for who to call.
Phase II (RCT): EDP Arm Caregivers
Enhanced Discharge Planning (EDP): EDP provides patients and caregivers a single session of education and skills training, symptom management, and support. The EDP participants received medication education, self-management strategies for symptoms, skills training, and a list of red flag symptoms and numbers for who to call.
Overall Study
STARTED
6
6
5
4
29
17
32
22
Overall Study
COMPLETED
3
3
5
4
21
11
20
15
Overall Study
NOT COMPLETED
3
3
0
0
8
6
12
7

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Phase Ia: 10-week Pre-pilot Patients
n=6 Participants
In this single arm pre-pilot, patients and caregiver dyads were offered a total of 12 contacts with a BOLSTER study nurse over 10 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase Ia: 10-week Pre-pilot Caregivers
n=6 Participants
In this single arm pre-pilot, patients and caregiver dyads were offered a total of 12 contacts with a BOLSTER study nurse over 10 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase Ib: 4-week Pre-pilot Patients
n=5 Participants
The second, abbreviated iteration of the intervention consisted of a single arm pre-pilot, in which patient and caregiver dyads were offered a total of 6 contacts with a BOLSTER study nurse over 4 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase Ib: 4-week Pre-pilot Caregivers
n=4 Participants
The second, abbreviated iteration of the intervention consisted of a single arm pre-pilot, in which patient and caregiver dyads were offered a total of 6 contacts with a BOLSTER study nurse over 4 weeks and daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice. Participants also had access to web-based symptom management and medical skills training.
Phase II (RCT): BOLSTER Arm Patients
n=29 Participants
BOLSTER provides participants with longitudinal nursing support across care settings, a smartphone-based symptom management app, a print and web-based symptom management toolkit, and advance care planning to ensure that the patient receives care that is congruent with her informed preferences. BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks. Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice.
Phase II (RCT): BOLSTER Arm Caregivers
n=17 Participants
BOLSTER provides participants with longitudinal nursing support across care settings, a smartphone-based symptom management app, a print and web-based symptom management toolkit, and advance care planning to ensure that the patient receives care that is congruent with her informed preferences. BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks. Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice.
Phase II (RCT): EDP Arm Patients
n=32 Participants
Enhanced Discharge Planning (EDP): EDP provides patients and caregivers a single session of education and skills training, symptom management, and support. The EDP participants received medication education, self-management strategies for symptoms, skills training, and a list of red flag symptoms and numbers for who to call.
Phase II (RCT): EDP Arm Caregivers
n=22 Participants
Enhanced Discharge Planning (EDP): EDP provides patients and caregivers a single session of education and skills training, symptom management, and support. The EDP participants received medication education, self-management strategies for symptoms, skills training, and a list of red flag symptoms and numbers for who to call.
Total
n=121 Participants
Total of all reporting groups
Age, Continuous
64 years
STANDARD_DEVIATION 7.31 • n=68 Participants
64 years
STANDARD_DEVIATION 6.63 • n=69 Participants
58 years
STANDARD_DEVIATION 14.03 • n=137 Participants
62 years
STANDARD_DEVIATION 12.48 • n=88 Participants
60 years
STANDARD_DEVIATION 10.17 • n=127 Participants
59 years
STANDARD_DEVIATION 9.54 • n=605 Participants
62 years
STANDARD_DEVIATION 7.51 • n=9 Participants
60 years
STANDARD_DEVIATION 10.21 • n=72 Participants
61 years
STANDARD_DEVIATION 9.46 • n=6 Participants
Sex: Female, Male
Female
6 Participants
n=68 Participants
1 Participants
n=69 Participants
5 Participants
n=137 Participants
1 Participants
n=88 Participants
25 Participants
n=127 Participants
10 Participants
n=605 Participants
31 Participants
n=9 Participants
7 Participants
n=72 Participants
86 Participants
n=6 Participants
Sex: Female, Male
Male
0 Participants
n=68 Participants
5 Participants
n=69 Participants
0 Participants
n=137 Participants
3 Participants
n=88 Participants
4 Participants
n=127 Participants
7 Participants
n=605 Participants
1 Participants
n=9 Participants
15 Participants
n=72 Participants
35 Participants
n=6 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
0 Participants
n=127 Participants
0 Participants
n=605 Participants
0 Participants
n=9 Participants
0 Participants
n=72 Participants
0 Participants
n=6 Participants
Race/Ethnicity, Customized
Asian
0 Participants
n=68 Participants
0 Participants
n=69 Participants
1 Participants
n=137 Participants
1 Participants
n=88 Participants
2 Participants
n=127 Participants
1 Participants
n=605 Participants
0 Participants
n=9 Participants
0 Participants
n=72 Participants
5 Participants
n=6 Participants
Race/Ethnicity, Customized
Black or African American
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
0 Participants
n=127 Participants
0 Participants
n=605 Participants
3 Participants
n=9 Participants
2 Participants
n=72 Participants
5 Participants
n=6 Participants
Race/Ethnicity, Customized
Native Hawaiian or Pacific Islander
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
1 Participants
n=605 Participants
0 Participants
n=9 Participants
0 Participants
n=72 Participants
2 Participants
n=6 Participants
Race/Ethnicity, Customized
White
6 Participants
n=68 Participants
6 Participants
n=69 Participants
4 Participants
n=137 Participants
3 Participants
n=88 Participants
24 Participants
n=127 Participants
14 Participants
n=605 Participants
26 Participants
n=9 Participants
20 Participants
n=72 Participants
103 Participants
n=6 Participants
Race/Ethnicity, Customized
Other
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
0 Participants
n=605 Participants
3 Participants
n=9 Participants
0 Participants
n=72 Participants
4 Participants
n=6 Participants
Race/Ethnicity, Customized
I don't know/refuse to answer
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
1 Participants
n=605 Participants
0 Participants
n=9 Participants
0 Participants
n=72 Participants
2 Participants
n=6 Participants
Ethnicity
Hispanic or LatinX
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
0 Participants
n=605 Participants
2 Participants
n=9 Participants
1 Participants
n=72 Participants
4 Participants
n=6 Participants
Ethnicity
Not Hispanic or LatinX
6 Participants
n=68 Participants
6 Participants
n=69 Participants
5 Participants
n=137 Participants
4 Participants
n=88 Participants
27 Participants
n=127 Participants
16 Participants
n=605 Participants
27 Participants
n=9 Participants
21 Participants
n=72 Participants
112 Participants
n=6 Participants
Ethnicity
Missing
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
1 Participants
n=605 Participants
3 Participants
n=9 Participants
0 Participants
n=72 Participants
5 Participants
n=6 Participants
Marital Status
Married
5 Participants
n=68 Participants
6 Participants
n=69 Participants
5 Participants
n=137 Participants
4 Participants
n=88 Participants
22 Participants
n=127 Participants
16 Participants
n=605 Participants
26 Participants
n=9 Participants
20 Participants
n=72 Participants
104 Participants
n=6 Participants
Marital Status
Divorced/Separated
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
2 Participants
n=127 Participants
0 Participants
n=605 Participants
2 Participants
n=9 Participants
2 Participants
n=72 Participants
6 Participants
n=6 Participants
Marital Status
Single, never married
1 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
2 Participants
n=127 Participants
0 Participants
n=605 Participants
2 Participants
n=9 Participants
0 Participants
n=72 Participants
5 Participants
n=6 Participants
Marital Status
Widowed
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
0 Participants
n=605 Participants
0 Participants
n=9 Participants
0 Participants
n=72 Participants
1 Participants
n=6 Participants
Marital Status
Partnered
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
1 Participants
n=605 Participants
1 Participants
n=9 Participants
0 Participants
n=72 Participants
3 Participants
n=6 Participants
Marital Status
I don't know/refused
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
0 Participants
n=605 Participants
1 Participants
n=9 Participants
0 Participants
n=72 Participants
2 Participants
n=6 Participants
Highest Level of Education
8th grade or less
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
0 Participants
n=127 Participants
0 Participants
n=605 Participants
0 Participants
n=9 Participants
0 Participants
n=72 Participants
0 Participants
n=6 Participants
Highest Level of Education
9 - 11th grade
0 Participants
n=68 Participants
0 Participants
n=69 Participants
1 Participants
n=137 Participants
0 Participants
n=88 Participants
0 Participants
n=127 Participants
0 Participants
n=605 Participants
1 Participants
n=9 Participants
0 Participants
n=72 Participants
2 Participants
n=6 Participants
Highest Level of Education
High school graduate / GED
1 Participants
n=68 Participants
2 Participants
n=69 Participants
0 Participants
n=137 Participants
1 Participants
n=88 Participants
1 Participants
n=127 Participants
2 Participants
n=605 Participants
3 Participants
n=9 Participants
1 Participants
n=72 Participants
11 Participants
n=6 Participants
Highest Level of Education
Vocational / Technical training
0 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
0 Participants
n=605 Participants
0 Participants
n=9 Participants
3 Participants
n=72 Participants
4 Participants
n=6 Participants
Highest Level of Education
Associate degree / some college
0 Participants
n=68 Participants
0 Participants
n=69 Participants
1 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
1 Participants
n=605 Participants
2 Participants
n=9 Participants
3 Participants
n=72 Participants
8 Participants
n=6 Participants
Highest Level of Education
Bachelor's degree
2 Participants
n=68 Participants
1 Participants
n=69 Participants
3 Participants
n=137 Participants
2 Participants
n=88 Participants
11 Participants
n=127 Participants
3 Participants
n=605 Participants
11 Participants
n=9 Participants
8 Participants
n=72 Participants
41 Participants
n=6 Participants
Highest Level of Education
Advanced degree
2 Participants
n=68 Participants
3 Participants
n=69 Participants
0 Participants
n=137 Participants
1 Participants
n=88 Participants
14 Participants
n=127 Participants
11 Participants
n=605 Participants
14 Participants
n=9 Participants
7 Participants
n=72 Participants
52 Participants
n=6 Participants
Highest Level of Education
Refuse to answer
1 Participants
n=68 Participants
0 Participants
n=69 Participants
0 Participants
n=137 Participants
0 Participants
n=88 Participants
1 Participants
n=127 Participants
0 Participants
n=605 Participants
1 Participants
n=9 Participants
0 Participants
n=72 Participants
3 Participants
n=6 Participants

PRIMARY outcome

Timeframe: 1 month

≥50% consent-to-approach ratio

Outcome measures

Outcome measures
Measure
Patients Approached
n=95 Participants
The number of patients that study staff approached regarding participation in the study
Phase II (RCT): BOLSTER Arm Caregivers
BOLSTER provides participants with longitudinal nursing support across care settings, a smartphone-based symptom management app, a print and web-based symptom management toolkit, and advance care planning to ensure that the patient receives care that is congruent with her informed preferences. BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks. Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice.
Feasibility of the BOLSTER Intervention
Consented
73 Participants
Feasibility of the BOLSTER Intervention
Did not consent
22 Participants

SECONDARY outcome

Timeframe: 3 months

≥70% participants "agree" or "strongly agree" that they would recommend BOLSTER to other patients; and ≥70% participants "agreed or "strongly agreed" that they were satisfied with the BOLSTER intervention. Note that this measure only includes data from the RCT portion of the study, as the Phases 1a and 1b were designed to refine the intervention.

Outcome measures

Outcome measures
Measure
Patients Approached
n=22 Participants
The number of patients that study staff approached regarding participation in the study
Phase II (RCT): BOLSTER Arm Caregivers
n=10 Participants
BOLSTER provides participants with longitudinal nursing support across care settings, a smartphone-based symptom management app, a print and web-based symptom management toolkit, and advance care planning to ensure that the patient receives care that is congruent with her informed preferences. BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks. Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice.
Acceptability of the BOLSTER Intervention
Acceptability - "I have been satisfied with the BOLSTER program sessions..." · Strongly agree
14 Participants
8 Participants
Acceptability of the BOLSTER Intervention
Acceptability - "I have been satisfied with the BOLSTER program sessions..." · Agree
6 Participants
2 Participants
Acceptability of the BOLSTER Intervention
Acceptability - "I have been satisfied with the BOLSTER program sessions..." · Neither agree nor disagree
2 Participants
0 Participants
Acceptability of the BOLSTER Intervention
Acceptability - "I would recommend the BOLSTER program to other patients..." · Strongly agree
16 Participants
8 Participants
Acceptability of the BOLSTER Intervention
Acceptability - "I would recommend the BOLSTER program to other patients..." · Agree
5 Participants
2 Participants
Acceptability of the BOLSTER Intervention
Acceptability - "I would recommend the BOLSTER program to other patients..." · Neither agree nor disagree
1 Participants
0 Participants

Adverse Events

Phase Ia: 10-week Pre-pilot Patients

Serious events: 0 serious events
Other events: 0 other events
Deaths: 3 deaths

Phase Ia: 10-week Pre-pilot Caregivers

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Phase Ib: 4-week Pre-pilot Patients

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Phase Ib: 4-week Pre-pilot Caregivers

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Phase II (RCT): BOLSTER Arm Patients

Serious events: 0 serious events
Other events: 0 other events
Deaths: 5 deaths

Phase II (RCT): BOLSTER Arm Caregivers

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Phase II (RCT): EDP Arm Patients

Serious events: 0 serious events
Other events: 0 other events
Deaths: 3 deaths

Phase II (RCT): EDP Arm Caregivers

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Alexi Wright

Dana-Farber Cancer Institute

Phone: 617-632-2334

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place